Skip to main content

Microbiologist is first in line for Oxford University's Covid-19 vaccine trial


Oxford University, AstraZeneca Join Forces for Coronavirus Vaccine ...


Elisha's name is not known. Elisa is 32 years old. The new Oxford vaccine was first given to him. If antibodies are made in the body, he will be given coronavirus. If the vaccine does not work, he may die. He has taken this risk for millions of people who will never be seen or recognized.

LONDON:microbiologist has become the first human to be injected for the human trial phase of a vaccine in the UK against the COVID-19 being developed by a group of scientists at the University of Oxford.

Elisa Granato is the first volunteer in an initial group of 800 to be part of the ground-breaking trial, which is hoped will be the answer for immunisation against the deadly virus and help with the easing of lockdown measures in place to curb its rapid transmission.

"I'm a scientist, so I wanted to try to support the scientific process wherever I can," Granato told the BBC as she was injected in Oxford, where the trial began this week.

“Since I don't study viruses I felt a bit useless these days, so I felt like this is a very easy way for me to support the cause,” she said, as she was injected on her 32nd birthday on Thursday.

Granato is joined by cancer researcher Edward O'Neill as the first two candidates – one of whom has been injected with the Covid-19 vaccine being trialled and the other a control vaccine which protects against meningitis.

They will now be monitored for 48 hours to observe the impact of each. Scientists will then gradually start injecting further volunteers, healthy individuals aged between 18 and 55, in a similar half-and-half process – with none of the participants aware which vaccine they have been injected with.


“Personally I have a high degree of confidence in this vaccine," said Sarah Gilbert, professor of vaccinology at the University of Oxford's Jenner Institute, who is leading the research.

"Of course, we have to test it and get data from humans. We have to demonstrate it actually works and stops people getting infected with coronavirus before using the vaccine in the wider population," she said, adding that she remains “very optimistic” about the outcome.

The team will know if the Covid-19 vaccine works by comparing the number of people who get infected with coronavirus in the months ahead from those in the trial.


Professor Andrew Pollard, director of the Oxford Vaccine Group, who is leading the trial, said: "We're chasing the end of this current epidemic wave. If we don't catch that, we won't be able to tell whether the vaccine works in the next few months.

“But we do expect that there will be more cases in the future because this virus hasn't gone away."

The researchers started screening healthy volunteers in March for the “ChAdOx1 nCoV-19” vaccine trial in the Thames Valley Region of England. ChAdOx1 nCoV-19 is made from a virus (ChAdOx1), which is a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees, that has been genetically changed so that it is impossible for it to grow in humans.
By vaccinating with ChAdOx1 nCoV-19, the Oxford University team is hoping to make the body recognise and develop an immune response to the spike protein that will help stop the SARS-CoV-2 or Covid-19 virus from entering human cells and therefore prevent infection.

Vaccines made from the ChAdOx1 virus have been given to more than 320 people to date and have been shown to be safe and well tolerated, although they can cause temporary side effects, such as a temperature, headache or sore arm.

Trial participants will be given an e-diary to record any symptoms experienced for seven days after receiving the vaccine. They will also record if they feel unwell for the following three weeks.

Following vaccination, participants will attend a series of follow-up visits. During these visits, the team will check participants' observations, take a blood sample and review the competed e-diary. These blood samples will be used to assess the immune response to the vaccine.

There is a theoretical risk that the virus could induce a serious reaction to coronavirus, but the scientists say that their data suggests the risk of the vaccine producing an enhanced disease is minimal.

The team has already developed a vaccine against Mers, another type of coronavirus, using the same approach – and that had promising results in clinical trials.

The researchers are prioritising the recruitment of local healthcare workers into the trial as they are more likely than others to be exposed to the virus. A larger trial, of about 5,000 volunteers, will start in the coming months and will have no age limit. The Oxford University team is also considering a vaccine trial in Africa, possibly in Kenya, where the rates of transmission are growing from a lower base.

The optimistic time-frame being looked at for around a million doses is by September. Deals have been done with UK and overseas manufacturers to make the vaccine at scale, should it prove effective.

The UK government has pumped in an extra 20 million pound into the University of Oxford trials and said that it is “throwing everything” at finding a vaccine against coronavirus, a crucial step to start lifting the strict social distancing lockdown measures in place to suppress the spread of the deadly virus.


source :https://m.economictimes.com/news/international/world-news/microbiologist-is-first-in-line-for-oxford-universitys-covid-19-vaccine-trial/articleshow/75348502.cms

Comments

Popular posts from this blog

Swami Vivekananda’s speech on 11th September, 1893 in Chicago

to listen his video of original voice click here Sisters and Brothers of America , It fills my heart with joy unspeakable to rise in response to the warm and cordial welcome which you have given us. I thank you in the name of the most ancient order of monks in the world; I thank you in the name of the mother of religions, and I thank you in the name of millions and millions of Hindu people of all classes and sects. My thanks, also, to some of the speakers on this platform who, referring to the delegates from the Orient, have told you that these men from far-off nations may well claim the  honor  of bearing to different lands the idea of toleration. I am proud to belong to a religion which has taught the world both tolerance and universal acceptance. We believe not only in universal toleration, but we accept all religions as true. I am proud to belong to a nation which has sheltered the persecuted and the refugees of all religions and all nations of the earth. I am ...

The life of Buddha

For forty-nine years , the Buddha of the world journeyed barefoot along the shores of the Ganges . He les us in the learning of the way to liberation , guiding us through the darkness like a path of light . The Buddha was born  a prince of the sakya clan , and was named siddhartha.  at birth sage predicted that he would grow up  to become a great holy king who would unify the world . as the future ruler of the sakya clan , price siddhartha lived a luxurious life comfort and pleasure in the palace. How,ever in search of the great way of  Liberation, to save all sentient beings from the cycle of birth and death; siddhartha left the palace on a white horse .He came to a forest at the foot of the snowy mountains; and there , he practiced asceticism . For six long years siddhartha endured every form of ascetic practices ,untill he finally realized that the middle path was the answer. Cultivation is like playing a musical string instrument . The string will snap i...

ISRO Chief K Sivan named for Von Karman Award 2020

Indian Space Research Organisation(ISRO) Chief,  Kailasavadivoo Sivan  has named for  Von Karman Award   2020  by the  International Academy of Astronautics (IAA) . The Von Karman Award is known as the highest distinction of the IAA. Dr K. Sivan is going to receive an award in March 2021 at Paris France. Prof.  Udupi Ramachandra Rao  was the first Indian to receive the von Karman award. The award was presented to him in  2005  and Dr  Krishnaswamy Kasturirangan  received the Von Karman award in  2007. Boost your Banking Awareness Knowledge with Adda247 Live Batch:  WARRIOR 2.0 | Banking Awareness Batch for SBI, RRB, RBI and IBPS Exams About von Karman Award: Important takeaways for all competitive exams: source: https://m.dailyhunt.in/news/india/english/adda247-epaper-adda/isro+chief+k+sivan+named+for+von+karman+award+2020-newsid-n198554864